First, early diagnosis of dermatomamyositis (DM) is a rare self-immuno-disease that primarily affects skin and muscle. Early diagnosis is essential to improve the prognosis, as timely treatment can slow the progress of disease and reduce the risk of complications. 1. Clinical performance: Early symptoms of piscitis may include muscle weakness, especially near muscles (e.g. hips, thighs, shoulder and neck muscles), which may lead to difficulties in walking, climbing stairs or starting from sit-ins. Skin symptoms include purple rashes, which are common on the face, neck, chest and joint sides, in particular the Gottron rash and the Heliotrope. In addition, patients may experience renox, joint pain and difficulty swallowing. Laboratory examinations: The blood tests usually show increases in levels of myo acid anase (CK), lactation dehydrase (LDH), formaldehyde enzyme (ALD), acetamase (ALT) and Zenitrochlorine aminoase (AST), which reflect muscle damage. In addition, the detection of anti-synthetic enzymes (e.g. anti-Jo-1 antibodies) and other self-antibodies contributes to the diagnosis and classification of piscitis. 3. Pathological work: muscular or skin work can show characteristic inflammation and muscular fibrosis. Muscle biopsy may indicate inflammation of inflammation cells, fibrosis and rebirth. Skin biopsy may indicate skin atrophy, skin inflammation and immersion of inflammation cells around the veins. EMG: The FEG can assess the muscle ‘ s electrical activity and show a change in the muscle ‘ s source, e.g., short time, low amplitude multiphase level. 5. Visual examination: MRI can assess muscle inflammation and oedema and help to determine the optimal location of the biopsy.
II. The treatment of common treatment drugs The treatment of psaicitis is aimed at controlling inflammation, mitigating symptoms, preventing complications and improving the quality of life. Cortical steroids: such as Penistone, are the first option for the treatment of dermatitis. The initial dose is usually high in order to control inflammation quickly and then gradually reduce to maintain stability. Long-term use can lead to a combination of osteoporosis, hypertension, diabetes and vulnerability. Immunosuppressants: e.g. aminophosphomide, cyclophosphate, sulfur, takmos, cyphenolate, etc., are used for the treatment of incorrigible piscitis or hormone in case of adverse effects. These drugs reduce reliance on cortical steroids, but may increase the risk of infection, damage to liver and kidney function, bone marrow inhibition, etc. 3. Biological agents: A single cloned antibodies for B cells, such as the Leathershield, are used to treat incurable skin mysticitis. Biological agents may increase the risk of infection and allergies. Janus hormone inhibitor**: e.g. Tofatini, used for the treatment of incurable piscitis. Such drugs may increase the risk of infection and damage to liver and kidney function. Antimalarial drugs, such as hydroxychloroquine, for treatment of persistent rashes. Long-term use can lead to retinasis and skin-colouring.
III. Sub-response management. Drugs for the treatment of dermatitis may have some side effects, and therefore there is a need to monitor closely the patient ‘ s condition and drug side effects during the treatment. Cortical steroids: Long-term use may lead to osteoporosis, hypertension, diabetes, vulnerability, etc. In order to reduce these side reactions, doctors may recommend the use of a minimum effective dose and take preventive measures such as calcium and vitamin D supplementation and regular examination of bone density. Immunosuppressants: may lead to increased risk of infection, damage to liver and kidney function, bone marrow suppression, etc. Regular blood examinations and liver and kidney function monitoring are essential for the early detection and treatment of these secondary reactions. 3. Biological agents: may lead to increased risk of infection, allergies, etc. Before beginning the treatment, the doctor assesses the overall health of the patient and closely monitors it during the treatment. Janus stressor: may lead to increased risk of infection, damage to liver and kidney function, etc. Blood and liver kidney functions are regularly monitored during treatment. Antimalarial drugs: may cause retinasis, skin-colouring, etc. Regular ophthalmological and skin examinations facilitate early detection and treatment of these secondary reactions. In sum, early diagnosis and treatment of piscitis requires a combination of factors, and the treatment requires close monitoring of the patient ‘ s condition and the drug response to achieve optimal treatment. Patients should work closely with doctors to develop individualized treatment programmes and take appropriate preventive measures to reduce the risk of drug side reactions.
